Skip to main content
. 2021 Apr 23;11:8816. doi: 10.1038/s41598-021-88086-x

Figure 2.

Figure 2

Showed PaO2/FiO2 variations after exposure of infected patients with COVID-19 to either tocilizumab or pulse Dexamethasone therapy. P ˂ 0.05 considered statistically significant.